157
Participants
Start Date
September 19, 2016
Primary Completion Date
May 24, 2019
Study Completion Date
May 24, 2023
ADSTILADRIN
Montefiore Medical Center, The Bronx
SUNY Upstate Medical Center, Syracuse
Penn State Milton S. Hershey Medical Center, Hershey
The Hospital of the University of Pennsylvania, Philadelphia
Thomas Jefferson University, Philadelphia
Johns Hopkins Kimmel Cancer Center, Baltimore
University of Virginia Health System, Charlottesville
Urology of Virginia, Virginia Beach
West Virginia University Cancer Institute, Morgantown
Duke University, Durham
Carolina Urologic research Center, Myrtle Beach
Regional Urology, Greenville
Emory University School of Medicine, Atlanta
University of Florida - UF Health Davis Center Pavilion and Shands Med Plaza, Gainesville
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Vanderbilt University Medical Center Dept. of Urologic Surgery, Nashville
University of Michigan, Ann Arbor
Spectrum Health Medical Group, Grand Rapids
University of Wisconsin - Madison, Madison
University of Minnesota, Minneapolis
Mayo Clinic - Rochester, Rochester
University of Chicago - Comprehensive Cancer Research Center, Chicago
Washington University School of Medicine, St Louis
Ochsner Clinic Foundation, New Orleans
The University of Oklahoma Health Sciences Center, Oklahoma City
University of Texas Southwestern Medical Center, Dallas
Baylor College of Medicine, Houston
MD Anderson Cancer Center, Houston
The Urology Center of Colorado, Denver
Banner MD Anderson Cancer Center, Gilbert
Keck School of Medicine at USC Medical Center, Los Angeles
Delaware Valley Urology, LLC, Voorhees Township
University of North Carolina (UNC) - Chapel Hill, Chapel Hill
The Univ. of Texas Health Science Center at San Antonio, San Antonio
Lead Sponsor
Collaborators (1)
FKD Therapies Oy
INDUSTRY
Society of Urologic Oncology Clinical Trials Consortium
OTHER
Ferring Pharmaceuticals
INDUSTRY